Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc., filed a Form 4 on November 19, 2026, disclosing two open-market purchases of common stock totaling 65,192 shares made on November 17 and November 18, 2026.
Key Highlights
- First purchase: Szela acquired 30,864 shares of common stock on November 17, 2026, at a weighted average price of $2.31 per share, with individual transaction prices ranging from $2.29 to $2.37.
- Second purchase: Szela acquired 34,328 shares of common stock on November 18, 2026, at a weighted average price of $2.59 per share, with individual transaction prices ranging from $2.44 to $2.65.
- Combined shares acquired: The two transactions total 65,192 shares acquired across both trading days.
- Resulting ownership: Following both transactions, Szela directly beneficially owns 1,140,182 shares of common stock, according to the filing.
- Roles: The filing identifies Szela as both a Director and an Officer (CEO and President) of TriSalus Life Sciences, Inc., listed on NASDAQ:TLSI.
Szela's Two-Day Common Stock Purchases at TriSalus Life Sciences
According to the Form 4 filed with the SEC on November 19, 2026, Mary T. Szela, CEO and President of TriSalus Life Sciences, Inc. (NASDAQ:TLSI), reported two separate open-market purchases of the company's common stock. Both transactions carry transaction code "P," indicating open-market purchases, and both are recorded as direct ownership.
On November 17, 2026, the filing discloses Szela acquired 30,864 shares at a weighted average price of $2.31. The filing notes these shares "were purchased in multiple transactions at prices ranging from $2.29 to $2.37 per share." Following this transaction, her directly held beneficial ownership stood at 1,105,854 shares. On November 18, 2026, she acquired an additional 34,328 shares at a weighted average price of $2.59, with individual transaction prices ranging from $2.44 to $2.65 per share, bringing her total direct beneficial ownership to 1,140,182 shares.
The filing states that Szela "undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range" for both transactions. No derivative securities transactions were reported. The form was signed by Mary Szela and dated November 19, 2026.
What Was Disclosed
TriSalus Life Sciences CEO and President Mary T. Szela disclosed two open-market purchases of common stock on November 17 and 18, 2026, acquiring a combined 65,192 shares, bringing her direct beneficial ownership to 1,140,182 shares.




Please wait processing your request...